MedPath
Found 6 clinical trials|View Analysis
Sort by:

A Study of MK-2060 in Healthy Participants (MK-2060-016)

Phase 1
Recruiting
Conditions
Venous Thrombosis
Interventions
Biological: MK-2060
Biological: Placebo
First Posted Date
2024-09-03
Last Posted Date
2024-12-18
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
64
Registration Number
NCT06582602
Locations
🇺🇸

Advanced Pharma CR, LLC ( Site 0002), Miami, Florida, United States

🇺🇸

Alliance for Multispecialty Research, LLC ( Site 0001), Knoxville, Tennessee, United States

Single Dose Study of MK-2060 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Older Japanese Participants on Dialysis (MK-2060-012)

Phase 1
Completed
Conditions
End-Stage Renal Disease (ESRD)
End-Stage Kidney Disease (ESKD)
Kidney Failure, Chronic
Interventions
Biological: MK-2060
Drug: Placebo
First Posted Date
2023-03-15
Last Posted Date
2024-02-22
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
17
Registration Number
NCT05769595
Locations
🇯🇵

Jomo Ohashi Clinic ( Site 1210), Maebashi, Gunma, Japan

🇯🇵

Keiaikai Nakamura Hospital ( Site 1213), Beppu, Oita, Japan

🇯🇵

Kasugai Municipal Hospital ( Site 1203), Kasugai, Aichi, Japan

and more 9 locations

A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011)

Phase 1
Completed
Conditions
End-Stage Renal Disease
End-Stage Kidney Disease
Kidney Failure, Chronic
Interventions
Drug: Placebo
Biological: MK-2060
First Posted Date
2022-12-19
Last Posted Date
2024-08-26
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
14
Registration Number
NCT05656040
Locations
🇺🇸

Advanced Pharma CR, LLC ( Site 0006), Miami, Florida, United States

🇺🇸

Alliance for Multispecialty Research, LLC ( Site 0002), Knoxville, Tennessee, United States

🇺🇸

Velocity Clinical Research, New Smyrna Beach ( Site 0003), Edgewater, Florida, United States

and more 1 locations

MK-2060 and Clopidogrel Co-administration Safety and Tolerability Study in Participants With End-Stage Renal Disease (ESRD) (MK-2060-008)

Phase 1
Completed
Conditions
Kidney Failure, Chronic
End-Stage Renal Disease
Interventions
Drug: MK-2060
First Posted Date
2022-04-19
Last Posted Date
2024-10-17
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
12
Registration Number
NCT05335005
Locations
🇮🇱

Hadassah Medical Center-Clinical Reaserch Unit ( Site 0002), Jerusalem, Israel

🇷🇴

ARENSIA Exploratory Medicine-Clinical Nephrology Hospital "Carol Davila" ( Site 0001), București, Bucuresti, Romania

🇺🇸

Genesis Clinical Research, LLC ( Site 0003), Tampa, Florida, United States

Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)

Phase 2
Active, not recruiting
Conditions
Kidney Failure, Chronic
End-Stage Renal Disease
End-Stage Kidney Disease
Interventions
Drug: MK-2060
Drug: Placebo
First Posted Date
2021-08-30
Last Posted Date
2024-12-05
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
506
Registration Number
NCT05027074
Locations
🇺🇸

Academic Medical Research Institute ( Site 0533), Los Angeles, California, United States

🇺🇸

Fresenius Kidney Care Newhope Fountain Valley ( Site 0617), Fountain Valley, California, United States

🇺🇸

DaVita Crescent Heights Dialysis Center ( Site 0574), Los Angeles, California, United States

and more 117 locations

Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)

Phase 1
Completed
Conditions
Renal Dialysis
Kidney Failure, Chronic
Interventions
Drug: MK-2060
Drug: Placebo
First Posted Date
2019-03-13
Last Posted Date
2024-06-06
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
38
Registration Number
NCT03873038
Locations
🇺🇸

New Orleans Center for Clinical Research ( Site 0001), Knoxville, Tennessee, United States

🇺🇸

Prism Research ( Site 0003), Saint Paul, Minnesota, United States

🇺🇸

Orlando Clinical Research Center ( Site 0002), Orlando, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath